| Literature DB >> 19417157 |
Galina Kuznetsov1, Qunli Xu, Lori Rudolph-Owen, Karen Tendyke, Junke Liu, Murray Towle, Nanding Zhao, Joanne Marsh, Sergei Agoulnik, Natalie Twine, Lana Parent, Zhihong Chen, Jue-Lon Shie, Yimin Jiang, Huiming Zhang, Hong Du, Roch Boivin, Yuan Wang, Daniel Romo, Bruce A Littlefield.
Abstract
We report here that des-methyl, des-amino pateamine A (DMDA-PatA), a structurally simplified analogue of the marine natural product pateamine A, has potent antiproliferative activity against a wide variety of human cancer cell lines while showing relatively low cytotoxicity against nonproliferating, quiescent human fibroblasts. DMDA-PatA retains almost full in vitro potency in P-glycoprotein-overexpressing MES-SA/Dx5-Rx1 human uterine sarcoma cells that are significantly resistant to paclitaxel, suggesting that DMDA-PatA is not a substrate for P-glycoprotein-mediated drug efflux. Treatment of proliferating cells with DMDA-PatA leads to rapid shutdown of DNA synthesis in the S phase of the cell cycle. Cell-free studies show that DMDA-PatA directly inhibits DNA polymerases α and γ in vitro albeit at concentrations considerably higher than those that inhibit cell proliferation. DMDA-PatA shows potent anticancer activity in several human cancer xenograft models in nude mice, including significant regressions observed in the LOX and MDA-MB-435 melanoma models. DMDA-PatA thus represents a promising natural product-based anticancer agent that warrants further investigation.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19417157 PMCID: PMC3026899 DOI: 10.1158/1535-7163.MCT-08-1026
Source DB: PubMed Journal: Mol Cancer Ther ISSN: 1535-7163 Impact factor: 6.261